Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Titre officiel

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Sommaire:

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumours.

Description de l'essai

Primary Outcome:

• The number of subjects with adverse events/serious adverse events
• The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.

Secondary Outcome:

• Percentage change in target lesion
• Objective Response Rate
• Duration of response
• Progression Free Survival
• Time to response
• Effects of AZD5305 on Ph2AX (Ser139) PD biomarker
• Module 1: Area under curve (AUC)
• Module 1: Maximum plasma concentration of the drug (Cmax)
• Module 1: The time taken to reach the maximum concentration (Tmax)
• Module 2: Area under curve (AUC)
• Module 2: Maximum plasma concentration of the drug (Cmax)
• Module 2: The time taken to reach the maximum concentration (Tmax)
• Module 3: Area under curve (AUC)
• Module 3: Maximum plasma concentration of the drug (Cmax)
• Module 3: The time taken to reach the maximum concentration (Tmax)

This study is a Phase I/IIa modular, open-label, multi-centre study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

Voir cet essai sur ClinicalTrials.gov